Search

Search Constraints

You searched for: Author/Creator Richardson, Debra

Search Results

1. 2022-RA-459-ESGO UPLIFT (ENGOT-ov67/GOG-3048) a registrational trial of Upifitamab Rilsodotin (XMT-1536; UpRi), a NaPi2b-directed antibody drug conjugate (ADC) in platinum-resistant ovarian cancer. (20th October 2022)

2. EP017/#425 Comparison of NAPI2B expression from paired tissue samples in a clinical study of upifitamab rilsodotin (UPRI; XMT-1536) supports a strategy of testing in archive material. (4th December 2022)

3. EP341/#510 Exploratory results of a phase IB trial of paclitaxel and carboplatin + galunisertib in patients with uterine and ovarian carcinosarcoma. (4th December 2022)

4. O012/#352 Atezolizumab and bevacizumab in recurrent endometrial cancer: a phase II, multi institutional trial. (4th December 2022)

5. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. Issue 5 (28th February 2020)

6. TP036/#426 Uplift (ENGOT-OV67/GOG-3048) a pivotal cohort of the XMT-1536–1 trial of upifitamab rilsodotin (XMT-1536; UPRI), a NAPI2B-directed antibody drug conjugate (ADC) in platinum-resistant ovarian cancer. (4th December 2022)

7. TP037/#453 Up-next (GOG-3049/ENGOT-OV71-NSGO-CTU): a study of upifitamab rilsodotin (UPRI), a NaPi2b -directed antibody drug conjugate (ADC) in platinum-sensitive recurrent ovarian cancer. (4th December 2022)